The two "troublemakers" on the global intellectual property rights scene in recent weeks, Brazil and Thailand (Marketletters passim), have agreed to "cooperate on health development," as well as on the manufacture of prescriptions drugs and vaccines.
Given the ongoing problems for the drug industry from both governments exploiting the letter of the World Trade Organization's agreement on Trade-Related on Intellectual Property Rights (TRIPs), coordinated action on future compulsory licenses, or even the mere threat of them, is bound to be unwelcome.
At the World Health Assembly in Geneva, Switzerland, the Brazilian representative called on the World Health Organization's Director General, Margaret Chan, to take a more "proactive" role in supporting the use of emergency measures by developing countries to overturn drug patents. At the same gathering, a Thai representative complained of "weak" leadership by the WHO on the issue of IPRs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze